Alpha-1-antitrypsin therapy ameliorates acute colitis and chronic murine ileitis

Inflammatory Bowel Diseases

Volumn 19, Issue 9, 2013, Pages 1964-1973

  Collins, Colm B ^a,b   Aherne, Carol M ^a,b   Ehrentraut, Stefan F ^a,c   Gerich, Mark E ^a,c   McNamee, Eóin N ^a,b   McManus, Martine C ^b   Lebsack, Matthew D P ^a   Jedlicka, Paul ^b   Azam, Tania ^d   De Zoeten, Edwin F ^a,b   Dinarello, Charles A ^d   Rivera Nieves, Jesús ^e  

^a Mucosal Inflammation Program   (United States)

^b Department of Pediatrics ^*  (United States)

^c Division of Gastroenterology   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Inflammation; Inflammatory bowel disease; Mucosal

Indexed keywords

ALPHA 1 ANTITRYPSIN; CXCL1 CHEMOKINE; INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROLASTIN C; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MEMBRANE PERMEABILITY; CLINICAL ARTICLE; COLITIS; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; DRUG SAFETY; EPITHELIUM CELL; EXPERIMENTAL MODEL; FLOW CYTOMETRY; HISTOLOGY; HUMAN; HUMAN TISSUE; ILEITIS; ILEUM; IN VIVO STUDY; INFLAMMATORY INFILTRATE; INTESTINE FUNCTION; INTESTINE MUCOSA PERMEABILITY; LYMPHOCYTE; MOUSE; NONHUMAN; PERMEABILITY BARRIER; PRIORITY JOURNAL; PROTECTION; TISSUE INJURY; WOUND HEALING;

ACUTE DISEASE; ALPHA 1-ANTITRYPSIN; ANIMALS; CELL MEMBRANE PERMEABILITY; CHRONIC DISEASE; COLITIS; CYTOKINES; DEXTRAN SULFATE; FLOW CYTOMETRY; HUMANS; ILEITIS; INFLAMMATION; MICE;

EID: 84884626693     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e31829292aa     Document Type: Article

References (36)

1. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003;3:521-533.
2. Lewis EC. Expanding the clinical indications for alpha-1-antitrypsin therapy. Mol Med. 2012;18:957-970.
3. Karbach U, Ewe K, Bodenstein H. Alpha 1-antitrypsin, a reliable endogenous marker for intestinal protein loss and its application in patients with Crohn's disease. Gut. 1983;24:718-723.
4. Gooptu B, Lomas DA. Conformational pathology of the serpins: themes, variations, and therapeutic strategies. Annu Rev Biochem. 2009;78:147-176.
5. Mulgrew AT, Taggart CC, McElvaney NG. Alpha-1-antitrypsin deficiency: current concepts. Lung. 2007;185:191-201.
6. Molmenti EP, Perlmutter DH, Rubin DC. Cell-specific expression of alpha 1-antitrypsin in human intestinal epithelium. J Clin Invest. 1993; 92:2022-2034.
7. Zhang B, Lu Y, Campbell-Thompson M, et al. Alpha1-antitrypsin protects beta-cells from apoptosis. Diabetes. 2007;56:1316-1323.
8. Pott GB, Chan ED, Dinarello CA, et al. Alpha-1-antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood. J Leukoc Biol. 2009;85:886-895.
9. Churg A, Dai J, Zay K, et al. Alpha-1-antitrypsin and a broad spectrum metalloprotease inhibitor, RS113456, have similar acute anti-inflammatory effects. Lab Invest. 2001;81:1119-1131.
10. Koulmanda M, Bhasin M, Hoffman L, et al. Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice. Proc Natl Acad Sci U S A. 2008;105:16242-16247.
11. Lewis EC, Shapiro L, Bowers OJ, et al. Alpha1-antitrypsin monotherapy prolongs islet allograft survival in mice. Proc Natl Acad Sci U S A. 2005; 102:12153-12158.
12. Lewis EC, Mizrahi M, Toledano M, et al. Alpha1-antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice. Proc Natl Acad Sci U S A. 2008;105:16236-16241.
13. Tawara I, Sun Y, Lewis EC, et al. Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation. Proc Natl Acad Sci U S A. 2011;109:564-569.
14. Yang P, Tremaine WJ, Meyer RL, et al. Alpha1-antitrypsin deficiency and inflammatory bowel diseases. Mayo Clin Proc. 2000;75:450-455.
15. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol. 2002;20:495-549.
16. Blumberg RS, Saubermann LJ, Strober W. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr Opin Immunol. 1999;11:648-656.
17. McNamee EN, Wermers JD, Masterson JC, et al. Novel model of T(H) 2-polarized chronic ileitis: the SAMP1 mouse. Inflamm Bowel Dis. 2010;16:743-752.
18. Parkos CA, Colgan SP, Bacarra AE, et al. Intestinal epithelia (T84) possess basolateral ligands for CD11b/CD18-mediated neutrophil adherence. Am J Physiol. 1995;268:C472-C479.
19. Ades EW, Candal FJ, Swerlick RA, et al. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol. 1992;99:683-690.
20. Lennon PF, Taylor CT, Stahl GL, et al. Neutrophil-derived 5'-adenosine monophosphate promotes endothelial barrier function via CD73-mediated conversion to adenosine and endothelial A2B receptor activation. J Exp Med. 1998;188:1433-1443.
21. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337:1029-1035.
22. Becker K, Berger M, Niederau C, et al. Individual fecal alpha 1-antitrypsin excretion reflects clinical activity in Crohn's disease but not in ulcerative colitis. Hepatogastroenterology. 1999;46:2309-2314.
23. Crama-Bohbouth G, Pena AS, Biemond I, et al. Are activity indices helpful in assessing active intestinal inflammation in Crohn's disease? Gut. 1989;30:1236-1240.
24. Aherne CM, Collins CB, Masterson JC, et al. Neuronal guidance molecule netrin-1 attenuates inflammatory cell trafficking during acute experimental colitis. Gut. 2011.
25. Karhausen J, Furuta GT, Tomaszewski JE, et al. Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J Clin Invest. 2004;114: 1098-1106.
26. Kuno Y, Ina K, Nishiwaki T, et al. Possible involvement of neutrophil elastase in impaired mucosal repair in patients with ulcerative colitis. J Gastroenterol. 2002;37(suppl 14):22-32.
27. Morohoshi Y, Matsuoka K, Chinen H, et al. Inhibition of neutrophil elastase prevents the development of murine dextran sulfate sodiuminduced colitis. J Gastroenterol. 2006;41:318-324.
28. Collins CB, Aherne CM, Kominsky D, et al. Retinoic acid attenuates ileitis by restoring the balance between T-helper 17 and T regulatory cells. Gastroenterology. 2011;141:1821-1831.
29. van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995;109:129-135.
30. Sartor RB. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology. 1994;106:533-539.
31. Taylor CT, Dzus AL, Colgan SP. Autocrine regulation of epithelial permeability by hypoxia: role for polarized release of tumor necrosis factor alpha. Gastroenterology. 1998;114:657-668.
32. Sikorski EE, Hallmann R, Berg EL, et al. The Peyer's patch high endothelial receptor for lymphocytes, the mucosal vascular addressin, is induced on a murine endothelial cell line by tumor necrosis factor-alpha and IL-1. J Immunol. 1993;151:5239-5250.
33. Schmitz H, Barmeyer C, Fromm M, et al. Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis. Gastroenterology. 1999;116:301-309.
34. Olson TS, Reuter BK, Scott KG, et al. The primary defect in experimental ileitis originates from a nonhematopoietic source. J Exp Med. 2006;203: 541-552.
35. Malyak M, Swaney RE, Arend WP. Levels of synovial fluid interleukin-1 receptor antagonist in rheumatoid arthritis and other arthropathies. Potential contribution from synovial fluid neutrophils. Arthritis Rheum. 1993; 36:781-789.
36. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998;41:2196-2204.